ViewPoint Therapeutics is a preclinical-stage biotech focused on discovering and developing small-molecule crystallin stabilizers to prevent and treat cataracts and presbyopia. Its lead candidate, VP1-001, is a small molecule targeting α-crystallin and is active in preclinical models of age-related cataracts. The company plans to use proceeds from the Series B to advance VP1-001 through clinical proof-of-concept studies in patients with cataracts and presbyopia and to progress second-generation compounds from ongoing medicinal chemistry efforts. ViewPoint was founded in 2014 based on research from the University of Michigan and Washington University in St. Louis and maintains a Scientific Advisory Board with expertise in protein misfolding and crystallin biology. The company emphasizes a non-surgical approach to vision loss and positions its program as potentially disruptive to the current surgical paradigm for cataracts. Financially, ViewPoint has closed a $35 million Series B to fund these development plans. ViewPoint Therapeutics is focused on developing small-molecule crystallin stabilizers to prevent or treat cataracts, presbyopia, and other disorders of aging linked to protein misfolding. Its lead candidate, VP1-001, is a small molecule active in preclinical models of age-related cataracts identified through target-based screening and optimization. The company is advancing second-generation compounds from ongoing medicinal chemistry efforts. ViewPoint plans to use recent funding to support preclinical proof-of-concept experiments for VP1-001 and to progress its chemistry program. The company was co-founded in 2014 and is based in San Francisco, CA. Leadership includes co-founders Dr. Jason Gestwicki, Dr. Leah Makley (CSO), and Ed Hurwitz (Executive Chairman).

Total raised

$39M

Funding rounds

2

Latest round

Series B

Latest activity

Mar 2018